Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml

KUMSAR, Şükrü; AYDEMİR, HÜSEYİN; SAĞLAM, Hasan Salih; Budak, Salih; köse, osman; ADSAN, Öztuğ

Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml

Hüseyin AYDEMİR, (Sakarya Üniversitesi Eğitim Araştırma Hastanesi Üroloji Anabilim Dalı, Sakarya, Türkiye)

Salih BUDAK, (Sakarya Üniversitesi Eğitim Araştırma Hastanesi Üroloji Anabilim Dalı, Sakarya, Türkiye)

Şükrü KUMSAR, (Sakarya Üniversitesi Eğitim Araştırma Hastanesi Üroloji Anabilim Dalı, Sakarya, Türkiye)

Osman KÖSE, (Sakarya Üniversitesi Eğitim Araştırma Hastanesi Üroloji Anabilim Dalı, Sakarya, Türkiye)

Hasan Salih SAĞLAM, (Sakarya Üniversitesi Eğitim Araştırma Hastanesi Üroloji Anabilim Dalı, Sakarya, Türkiye)

Öztuğ ADSAN (Sakarya Üniversitesi Eğitim Araştırma Hastanesi Üroloji Anabilim Dalı, Sakarya, Türkiye)

Journal of Clinical and Analytical Medicine

0 0

Yıl: 2015 Cilt: 6 Sayı: 3 Sayfa Aralığı: 320 - 323 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml

Öz:

Amaç: Bu çalışmada kliniğimizde prostat spesifik antijen (PSA) 4 ng/ml ve altında değerlere sahip hastaların transrektal ultrasonografi (TRUS) eşliğindeyapılmış olan prostat biyopsilerinin histopatolojik sonuçlarının değerlendirilmesi amaçlandı. Gereç ve Yöntem: Kliniğimizde Ocak 2010-Şubat 2013 tarihleri arasında prostat kanseri şüphesi nedeniyle prostat biyopsisi yapılan 524hastadan PSA değerleri 4 ng/ml ve altında olan 43 olgu histopatolojik sonuçları ile retrospektif olarak değerlendirildi. Bulgular: Hastaların yaş ortalaması 64.63 ±7.42 olup ortalama PSA değeri 2.89 ±0.88 ng/ml idi. Hastaların 41(%95.34) inde parmakla rektal muayenede (PRM) şüpheli bulgu vardı. Hastaların biyopsi sonucunda 13 (%30.23) hastada prostat adenokarsinom tespit edildi. Bu hastaların ortalama PSA değerleri 2.52 ±1.21 ng/ml olup ortalama gleason skorları ise 6.41 ±0.87 idi. Ortalama prostat volümleri 41.46±11.95 cm3 olarak tespit edildi. Tartışma: Çalışmamızda PSA 4 ng/mlnin altında %30.3 oranında prostat kanseri saptanmıştır. PRM, prostat değerlendirilmesinde halen önemini korumaktadır. Sonuçlarımız PSA 4 ng/mlnin altındaanlamlı sayıda kanser tespit edildiğini göstermektedir.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Prostat spesifik antijen 4 ng/ml nin altındaki hastalarda prostat biyopsi sonuçlarımız

Öz:

Aim: The aim of this study is to evaluate the re¬sults of prostate biopsy ofpatients who had the prostate-specifc antigen (PSA) levels below 4 ng/ml.Material and Method: The medical records of 524 pa¬tients who underwenttransrectal prostate biopsy be¬tween January 2010 and February 2013 in ourclinic, due to suspi¬cion of prostate cancer were evaluated and histopathoogic results of 43 patients whose PSA levels under 4 ng/ml were retrospectively revieved. Results: The mean age of patients was 64.63 ±7:42 and themean level of PSA was 2.89 ±0.88ng /ml. A digital rectal examination (DRE)had suspicious fndings in 41(95.34%) patients. Prostate adenocarcinomawas determined in 13 of (30.23%) patients according to the biopsy result.The mean PSA value of these patients was 2.89 ±0.88 ng/ml and the meangleason score of these patients was 6.41 ±0.87. The mean prostate volumeof these patients was 41.46 ±11.95 cm3. Discussion: In our study, prostatecancer was identifed in 30.3% of patients whose PSA levels were below 4ng/ml. DRE, is still important for the evaluation of the prostate. Accordingto our results, signifcant number of cancers can be detected in PSA below4 ng/ml levels.

Anahtar Kelime:

Konular: Genel ve Dahili Tıp

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Polascik TJ, Oesterling JE,Partin AW. Prostate specific antigen: a decade of discovery what we have learned and where we are going. J Urol 1999;162:293-306.
2. Heidenreich A, Bastian PJ, Bellmunt J,M. Bolla,S. Joniau, T.H. van der Kwast, et al. Guidelines on Prostate Cancer. EAUPG 2013;41-59.
3. Ballentine CH, Peter CA, Michael JB, Ruth E, Stephen JF, Kirsten LG, et al. Early detection of prostate cancer. American Urological Association (AUA) Guideline. J Urol 2013;190(2):419-26.
4. Sandblom G, Varenhorst E, Rosell J, Löfman O, Carlsson P. Randomised prostate cancer screening trial: 20 year follow up. BMJ 2011;342:1539.
5. Catalona WJ, Loeb A. The PSA era is not over for prostate cancer. Eur Urol 2005;48:541-5.
6. Catalona WJ, Smith DS, Ratlif TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
7. Cooner WH, Mosley BR, Rutherford CL, Beard JH, Pond HS, Terry WJ et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990;143:1146-52.
8. Catalona WJ, Hudson MA, Scardino PT. Selection of optimal prostate specific antigen cutofs for early detection of prostate cancer: receiver operating characteristic curves. J Urol 1994;152:2037-42.
9. Thompson IM, Pauler DK, Goodman PJ. Prevalence of prostate cancer among menwith a prostate specific antigen level _____ 4.0 ng per milliliter. N Engl J Med 2004;350(2):223946.
10. Gilbert SM, Cavallo CB, Kahane H, Lowe FC. Evidence suggesting PSA cutpo- int of 2.5 ng/mL for prompting prostate biopsy: review of 36,316 biopsies. Uro- logy 2005;65:54953.
11. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, DownsJ. The prostate specific antigen era in the United States is over for prostate cancer: what happe- ned in the last 20 years? J Urol 2004;172:1297-01.
12. Jang TL, Han M, Roehl KA, Hawkins SA, Catalona WJ. More favorable tumor fe- atures and progression free survival rates in a longitudinal prostate cancer screening study: PSA era and threshold-specific efects. Urology 2006;67:343-8.
13. Zhu H, Roehl KA, Antenor AV, Catalona WJ. Biopsy of men with PSA level of 2.6 to 4.0 ng/ml associated with favorable pathologic features and PSA progression rate: a preliminary analysis. Urology 2005;66:547-51.
14. Yossepowitch O, Eggener SE, Bianco FJ Jr, Carver BS, Serio A, Scardino PT et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007;178(2):493-9.
15. Wilt TJ. The prostate cancer ıntervention versus observation trial: VA/NCI/ AHRQ cooperative studies program: design and baseline results of a randomized controlled trial comparing radical prostatectomy with watchful waitingfor men with clinically localized prostate cancer. J Natl Cancer Inst Monogr 2012;2012(45):184-90.
16. Jung K, Meyer A, Lein M, Rudolph B, Schnorr D. and Loening SA. Ratio of free- tototal prostate specific antigenin serum can not distinguish patients with prostate cancer from those chronic infammation of the prostate. J Urol 1998;159:1595- 8.
17. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance diferentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998;279:1542-7.
18. Lee R, Localio AR, Armstrong K, Malkowicz SB, Schwartz JS. A meta-analysis of the performance characteristics of the free prostate-specific antigentest. Urology 2006;67:762-8.
19. Stephan C, Stroebel G, Heinau M, Lenz A, Roemer A, Lein M, et al. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of _____ 4 ng/mL. Cancer 2005;104(5):993-1003.
20. Sokoll LJ, Sanda MG, Feng Z, Kagan J, Mizrahi IA, Broyles DL, et al. A prospective, multicenter, National Cancer Institute Early Detection Research Network study of proPSA: improving prostate cancer detection and correlating with cancer agg- ressiveness. Cancer Epidemiol Biomarkers Prev 2010;19:1193-200.
21. Le BV, Grifin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA, et al. Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in diferentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 2010;183:1355-9.
22. Bradley LA, Palomaki GE, Gutman S, Samson D, Aronson N. Comparative Efectiveness Review: Prostate Cancer Antigen 3 Testing for the Diagnosis and Management of Prostate Cancer. J Urol 2013;190(2):389-9.

APA	AYDEMİR H, Budak S, KUMSAR Ş, köse o, SAĞLAM H, ADSAN Ö (2015). Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml. , 320 - 323.
Chicago	AYDEMİR HÜSEYİN,Budak Salih,KUMSAR Şükrü,köse osman,SAĞLAM Hasan Salih,ADSAN Öztuğ Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml. (2015): 320 - 323.
MLA	AYDEMİR HÜSEYİN,Budak Salih,KUMSAR Şükrü,köse osman,SAĞLAM Hasan Salih,ADSAN Öztuğ Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml. , 2015, ss.320 - 323.
AMA	AYDEMİR H,Budak S,KUMSAR Ş,köse o,SAĞLAM H,ADSAN Ö Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml. . 2015; 320 - 323.
Vancouver	AYDEMİR H,Budak S,KUMSAR Ş,köse o,SAĞLAM H,ADSAN Ö Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml. . 2015; 320 - 323.
IEEE	AYDEMİR H,Budak S,KUMSAR Ş,köse o,SAĞLAM H,ADSAN Ö "Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml." , ss.320 - 323, 2015.
ISNAD	AYDEMİR, HÜSEYİN vd. "Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml". (2015), 320-323.

APA	AYDEMİR H, Budak S, KUMSAR Ş, köse o, SAĞLAM H, ADSAN Ö (2015). Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml. Journal of Clinical and Analytical Medicine, 6(3), 320 - 323.
Chicago	AYDEMİR HÜSEYİN,Budak Salih,KUMSAR Şükrü,köse osman,SAĞLAM Hasan Salih,ADSAN Öztuğ Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml. Journal of Clinical and Analytical Medicine 6, no.3 (2015): 320 - 323.
MLA	AYDEMİR HÜSEYİN,Budak Salih,KUMSAR Şükrü,köse osman,SAĞLAM Hasan Salih,ADSAN Öztuğ Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml. Journal of Clinical and Analytical Medicine, vol.6, no.3, 2015, ss.320 - 323.
AMA	AYDEMİR H,Budak S,KUMSAR Ş,köse o,SAĞLAM H,ADSAN Ö Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml. Journal of Clinical and Analytical Medicine. 2015; 6(3): 320 - 323.
Vancouver	AYDEMİR H,Budak S,KUMSAR Ş,köse o,SAĞLAM H,ADSAN Ö Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml. Journal of Clinical and Analytical Medicine. 2015; 6(3): 320 - 323.
IEEE	AYDEMİR H,Budak S,KUMSAR Ş,köse o,SAĞLAM H,ADSAN Ö "Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml." Journal of Clinical and Analytical Medicine, 6, ss.320 - 323, 2015.
ISNAD	AYDEMİR, HÜSEYİN vd. "Our prostate biopsy results in the patients with prostate specifc antigen levels below 4 ng/ml". Journal of Clinical and Analytical Medicine 6/3 (2015), 320-323.